Table 3.
Toxicities
| Short-term Toxicities Secondary to BRAF/MEK Inhibitor Therapy | n (%) |
|---|---|
| Short-term Toxicities | 120 (82.2) |
| Grade | n (% of those with short-term toxicities) |
| 1 | 77 (64.2) |
| 2 | 53 (44.2) |
| 3+ | 29 (24.2) |
| Dose Adjustments Secondary to Toxicities | 73 (60.8) |
| Ceased | 3 (2.5) |
| Dose reduction | 23 (19.2) |
| Intermittent dosing | 26 (21.7) |
| Treatment break | 9 (7.5) |
| Treatment break and dose reduction | 12 (10.0) |
| Switched Regimens Secondary to Toxicities | 17 (14.2) |
| Short-term Toxicity Type * | |
| Fever/chills | 50 (41.7) |
| Fatigue | 21 (17.5) |
| Arthritis/arthralgias | 18 (15.0) |
| GI (nausea, vomiting, diarrhea) | 45 (37.5) |
| Cutaneous (rash, pruritis, photosensitivity) | 44 (36.7) |
| Cardiac | 9 (7.5) |
| Ocular | 22 (18.3) |
| Ongoing Toxicities at Last Follow-up | 13 (10.8) |
| Grade | n (% of those with ongoing toxicities) |
| 1 | 8 (61.5) |
| 2 | 5 (38.5) |
| 3 | 1 (7.7) |
| Unknown | 2 (15.4) |
| Ongoing Toxicity Type ** | |
| Anterior uveitis | 1 (7.7) |
| Arthralgias/myalgias | 7 (53.8) |
| Cutaneous | 4 (30.8) |
| Dysgeusia/xerostomia | 1 (7.7) |
| Fatigue | 4 (30.8) |
| Fever | 1 (7.7) |
| Pneumonitis | 1 (7.7) |
| GI upset | 2 (15.4) |
| Neuropathy | 2 (15.4) |
| Neutropenia | 1 (7.7) |
| Intermittent weight gain | 1 (7.7) |
*
>5% prevalence
**
8 patients had >/= 2 distinct ongoing toxicities
***
Erythema nodosum (n=1), erythema (n=1), toe lesion (n=1), rash (n=1)